Baseline characteristics of patients with active ANCA–associated vasculitis at presentation
| . | Normal range . | N = 71 . |
|---|---|---|
| Male (%) | 43 (61) | |
| Age in y (±SD) | 62 (±13) | |
| BMI (IQR) | 18.5-25 | 26.2 (24.1-29.6) |
| Diagnosis (%) | ||
| MPA | 22 (31) | |
| GPA | 49 (69) | |
| ANCA (%) | ||
| MPO | 29 (41) | |
| PR3 | 40 (56) | |
| Double positive | 2 (3) | |
| De novo presentation, (%) | 39 (55) | |
| BVAS (±SD) | 14 (±4) | |
| Organ involvement (%) | ||
| General | 42 (59) | |
| Cutaneous | 6 (9) | |
| Mucous membranes | 4 (6) | |
| ENT | 38 (54) | |
| Chest | 34 (49) | |
| Cardiovascular | 2 (3) | |
| Abdominal | 0 (0) | |
| Renal | 46 (65) | |
| Nervous system | 8 (11) | |
| Remission-induction scheme (%) | ||
| RTX | 36 (51) | |
| RTX/CYC | 16 (22) | |
| CYC | 19 (27) | |
| Dialysis at presentation (%) | 1 (1) | |
| Time to ≤5 mg prednisone in days (IQR) | 105 (77-140) | |
| Previous thrombotic events (%) | 4 (6) | |
| Laboratory parameters | ||
| Hemoglobin (±SD) | 8.2-11.0∗/7.3-9.7† mmol/L | 7.2 (±1.2) |
| Platelet (IQR) | 130-350 ×109/L | 332 (264-394) |
| Leukocytes (IQR) | 3.5-11.0 ×109/L | 8.5 (6.7-12.1) |
| Serum creatinine (IQR) | 60-115 μmol/L | 150 (95-234) |
| CRP (IQR) | <10 mg/L | 20 (8-45) |
| IgG (±SD) | 7.0-16.0 g/L | 11.7 (±3.3) |
| ANCA level (IQR) | MPO ≤ 5.0 IU/mL PR3 ≤ 3.0 IU/mL | 72 (30-120) |
| . | Normal range . | N = 71 . |
|---|---|---|
| Male (%) | 43 (61) | |
| Age in y (±SD) | 62 (±13) | |
| BMI (IQR) | 18.5-25 | 26.2 (24.1-29.6) |
| Diagnosis (%) | ||
| MPA | 22 (31) | |
| GPA | 49 (69) | |
| ANCA (%) | ||
| MPO | 29 (41) | |
| PR3 | 40 (56) | |
| Double positive | 2 (3) | |
| De novo presentation, (%) | 39 (55) | |
| BVAS (±SD) | 14 (±4) | |
| Organ involvement (%) | ||
| General | 42 (59) | |
| Cutaneous | 6 (9) | |
| Mucous membranes | 4 (6) | |
| ENT | 38 (54) | |
| Chest | 34 (49) | |
| Cardiovascular | 2 (3) | |
| Abdominal | 0 (0) | |
| Renal | 46 (65) | |
| Nervous system | 8 (11) | |
| Remission-induction scheme (%) | ||
| RTX | 36 (51) | |
| RTX/CYC | 16 (22) | |
| CYC | 19 (27) | |
| Dialysis at presentation (%) | 1 (1) | |
| Time to ≤5 mg prednisone in days (IQR) | 105 (77-140) | |
| Previous thrombotic events (%) | 4 (6) | |
| Laboratory parameters | ||
| Hemoglobin (±SD) | 8.2-11.0∗/7.3-9.7† mmol/L | 7.2 (±1.2) |
| Platelet (IQR) | 130-350 ×109/L | 332 (264-394) |
| Leukocytes (IQR) | 3.5-11.0 ×109/L | 8.5 (6.7-12.1) |
| Serum creatinine (IQR) | 60-115 μmol/L | 150 (95-234) |
| CRP (IQR) | <10 mg/L | 20 (8-45) |
| IgG (±SD) | 7.0-16.0 g/L | 11.7 (±3.3) |
| ANCA level (IQR) | MPO ≤ 5.0 IU/mL PR3 ≤ 3.0 IU/mL | 72 (30-120) |
ANCA, antineutrophil cytoplasmic antibody; BMI, body mass index; CRP, C-reactive protein; CYC, cyclophosphamide; ENT, ear, nose, and throat; GPA, granulomatosis with polyangiitis; IgG, immunoglobulin G; IQR, interquartile range; MPA, microscopic polyangiitis; MPO, myeloperoxidase; PR3, proteinase 3; RTX, rituximab; SD, standard deviation.
Normal hemoglobin ranges for males.
Normal hemoglobin ranges for females.